Revolade approved for use in hepatitis C therapyRevolade, a platelet-boosting drug marketed by GlaxoSmithKline (GSK), has achieved EU approval. The drug treats patients whose low blood platelet count is adversely affecting the work of therapies to fight the hepatitis C virus.

New comprehensive all-oral regimens would impact upon the need for Revolade but GSK believe the drug can still strongly benefit patients using the drug with low platelet counts.

Read our article on Revolade here:


Hepatitis C News

The team at works hard to deliver relevant and accessible information on hepatitis C, an infectious liver disease that affects around 150 million people worldwide. Updated daily, features topical news stories from around the world, tips and advice on living well with the hep C virus and guest blogs. Often referred to as a silent disease, as in most cases it does not result in any symptoms, hepatitis C is most commonly transmitted through contact with an infected person’s blood. The hepatitis C virus can cause serious damage to the liver and, if left untreated, can result in scarring of the liver, liver disease or even death.

Add a comment

Your email address will not be published. Required fields are marked *